Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome
Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome
复制标题
达那肝素对于产科抗磷脂综合征患者有效且安全
DOI：
10.1080/14397595.2019.1602241
复制
发表时间：
2019
影响因子：
2.2
通讯作者：
Ozaki Yasuhiko
中科院分区：
文献类型：
--
作者：
Yoshihara Hiroyuki;Sugiura-Ogasawara Mayumi;Kitaori Tamao;Katano Kinue;Ozaki Yasuhiko
目的：探讨达那肝素对产科抗磷脂综合征（oAPS）患者活产率的影响。方法：本前瞻性研究纳入了60例oAPS患者的91例妊娠，根据国际APS大会标准诊断为oAPS。比较了接受达那肝素和低剂量阿司匹林（达那肝素组，LDA）、普通肝素（UFH）和LDA（UFH组）以及LDA和/或泼尼松龙（LDA组）治疗的患者的活产率、不良妊娠和围产期结局。结果：排除11例胚胎染色体异常流产、1例化学妊娠和1例异位妊娠后，达那肝素组活产率为87.5%（14/16），UFH组为90.0%（36/40），LDA组为63.6%（14/22）。达那肝素和UFH治疗的患者的活产率相似，并且倾向于分别高于LDA治疗的患者（OR 4.0，95%置信区间0.72-22.22和5.15，1.33-20.00）。没有接受达那肝素的患者和1例UFH患者发生肝素诱导的血小板减少症，导致死胎。结论：达那肝素对oAPS患者安全，能有效提高活产率。
Objectives:The objective is to evaluate whether danaparoid is effective in improving the live birth rate in patients with obstetric antiphospholipid syndrome (oAPS).Methods:This prospective study included 91 pregnancies of 60 patients with oAPS diagnosed according to criteria of the International Congress on APS. Live birth rates, adverse pregnancies and perinatal outcomes were compared among patients treated with danaparoid and low dose aspirin (danaparoid group, LDA), unfractionated heparin (UFH) and LDA (UFH group) and LDA and/or prednisolone (LDA group).Results:After excluding 11 miscarriages with abnormal embryonic chromosomes, one chemical pregnancy and one ectopic pregnancy, live birth rates were 87.5% (14/16) for the danaparoid group, 90.0% (36/40) for the UFH group and 63.6% (14/22) for the LDA group, respectively. The live birth rates of patients treated with danaparoid and UFH were similar and tended to be higher than that of patients treated with LDA, respectively (OR 4.0, 95% confidence interval 0.72–22.22 and 5.15, 1.33–20.00). No patient given danaparoid and one patient with UFH developed heparin-induced thrombocytopenia which resulted in a stillbirth. Another patient with UFH suffered a lumbar compression fracture.Conclusion:Danaparoid is effective for improving the live birth rate and is safe for patients with oAPS.
登录
查看更多内容
影响因子：
158.5
作者：
Rand, JH;Wu, XX;Harpel, PC
通讯作者：
Harpel, PC
影响因子：
10.4
作者：
Chong, BH
通讯作者：
Chong, BH
影响因子：
--
作者：
Lockshin, Michael D.;Kim, Mimi;Laskin, Carl A.;Guerra, Marta;Branch, D. Ware;Merrill, Joan;Petri, Michelle;Porter, T. Flint;Sammaritano, Lisa;Stephenson, Mary D.;Buyon, Jill;Salmon, Jane E.
通讯作者：
Salmon, Jane E.
在出血并发症患者的急性血液透析期间使用新型肝素作为抗凝剂
DOI：
10.1016/s0140-6736(83)91326-0
发表时间：
1983
期刊：
The Lancet
影响因子：
--
作者：
C. Henny;J. T. Gate;H. Bronswijk;H. Cate;S. Surachno;J. Wilmink;P. Ockelford
通讯作者：
P. Ockelford
影响因子：
6.7
作者：
Sugiura-Ogasawara, Mayumi;Ozaki, Yasuhiko;Suzuki, Sadao
通讯作者：
Suzuki, Sadao